Over the past several years, we have seen accelerating technological change. Machine learning is accelerating drug discovery, genomic datasets are training neural models, and brain-computer interfaces are moving on from clinical trials into real-world applications. This superconvergence of AI, biology, and computing is compressing decades of progress into years and creating possibilities that none of these fields could generate alone.
Mostly in their earliest phases, newer biotechnology fields are pushing the boundaries of science by unifying innovative technologies and biology. With AI, intelligent models trained on health and biological data are being used to develop intelligent routine applications, such as chatbots and wellness assistants.
Key outputs of this technical evolution include integrated clinical life-support systems, automated assay platforms, and sophisticated edge-computing applications and wearables that enable continuous, non invasive health surveillance. Digital asset company Tether is dedicating resources to developing systems that advance humanity through the integration of AI, robotics, and biology.
Tether is leading advancements in biotechnology
Tether’s Brain-Computer Interface (BCI) operational stack, BrainOS, combines intelligent inference models, speech recognition models, and cutting-edge physical technologies, creating a new field – Physical AI, where Tether Data and Tether Evo converge to accelerate biotechnological advancement.
QVAC (QuantumVerse Automatic Computer) is Tether’s answer to centralized AI, Peer-to-peer AI, which runs privately, locally, and without permission. Current contributions include the underlying module for Tether’s BrainWhisperer, which handles brain-signal translation; the QVAC MedPsy, a high-performance, 1.7-billion parameter, edge-optimized, local-first medical AI model; and theQVAC SDK, which packages these reusable modules for developers across diverse biotech and AI fields.
On March 16, 2026, Tether announced that 4 of its research papers had been successfully submitted and accepted for presentation at the International Conference on Learning Representations (ICLR) (Re-align workshop), which recognizes significant research breakthroughs in this field. These studies aim to improve clinical understanding of brain activity in normal and speech-impaired patients, creating opportunities for advanced integration with external systems to support further research and the management of related conditions.
The most immediate application of this is in brain-to-text translation, where Tether’s prototype has successfully transcribed single and batched intracortical signals into words with less than 2% WER (Word Error Rate), setting a new standard in a field regarded as the next frontier of biotechnological evolution. Brain-to-text technology, in its current phase, focuses on accurately translating neural signals into plain text for communication. This is relevant in cases of neuronal degeneration, where it bypasses damaged neural pathways to restore speech to people suffering from ALS (Amyotrophic Lateral Sclerosis), Locked-in syndrome, and other paralysis conditions.
However, this is only a stage-setter for more advanced use cases. BCIs will be able to instruct and communicate with prosthetics and external devices, such as AI-assisted Robotic Arms (ARA).
Maintaining a ‘human-first’ development culture
For Tether, it’s not just about unifying AI and biotechnology to develop effective biotechnological products, but also about reflecting positive societal values in its operations. Acknowledging the importance of advanced biotech to 100% of the global population, Tether believes that users should fully control innovations in this field. “Users” refers to the humans, robotic prostheses, and AI agents that, in the near future, will interact autonomously.
Given that the most effective BCI experiments are invasive, the direct interaction with the human system raises several ethical questions regarding the security, safety, and privacy of a technology that “reads the human mind.” Tether acknowledges these concerns and embeds the solutions directly into its architecture.
By localizing user data and preventing upstreaming to centralized data centers, Tether’s BCI technology is hardcoded against adversarial attacks and brain tapping in the form described by the WEF, as well as more advanced attacks. Users take charge of their data, which actually never leaves the interfacing devices. This way, neural data cannot be manipulated or used in surveillance schemes.
The peer-based backend prevents third-party access at the point of operation. Even the model and protocol developers cannot intercept the flow of information between the BCI implants and the interfacing device.
According to CEO, Paolo Ardoino,
“…it’s crucial that this potentially invasive technology be in the public domain and not owned by a few entities. Tether is therefore interested in developing it openly and in collaboration with universities worldwide, allowing free access to the technology.”
Superconvergence goes beyond the interconnection of disciplines; it includes the interconnection of people. Through open-sourcing, Tether shares its technology with millions of developers, auditors, and researchers. With an unlimited supply of scrutiny for every piece of code, experiment, and final product, it aims to maintain the highest standards of quality, transparency, and true user control. This applies to its biotech research.
Future-proofing superconvergence for biotechnological advancements
The only way to push civilization forward is to unify advancements across multiple disciplines. Standalone systems can only do so much. Superconvergence breaks systemic limitations and opens troves of opportunities. The early breakthroughs give insight into the infinite potential. Tether has built a system to pursue these potentials and scale it indefinitely.
Discover how Tether is using AI and biotechnology to improve lives.
